M2 PHARMA-December 19, 2017-GlycoMimetics to Join
NASDAQ Biotechnology Indexdeclared that it has been chosen or inclusion to the
NASDAQ Biotechnology Index.
The
Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the
NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
According to Evaluate Pharma, the
NASDAQ Biotechnology index grew by 66% in 2013.
The
Nasdaq biotechnology index fell seven per cent for the week.
Biotechnology companies in particular had a standout 2013, with the
Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
M2 EQUITYBITES-December 24, 2013-Agios Pharmaceuticals announces addition to
Nasdaq Biotechnology IndexThe firm cites the iShares
NASDAQ biotechnology Index, the SPDR S&P Biotech ETF and the First Trust AMEX biotechnology Index ETF, which have all gained over 20% in the past year and outperformed the broader markets by a good margin.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the
NASDAQ Biotechnology Index for a single day.
AVANIR Pharmaceuticals has been selected for addition to the
NASDAQ Biotechnology Index effective Monday, November 20.
has been selected for inclusion in the
Nasdaq Biotechnology Index, which tracks the performance of the pharmaceutical and biotechnology market sectors.
